Analysts predict that Editas Medicine Inc (NASDAQ:EDIT) will post earnings per share of ($0.79) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Editas Medicine’s earnings. The highest EPS estimate is ($0.62) and the lowest is ($1.36). Editas Medicine posted earnings per share of ($1.10) during the same quarter last year, which would indicate a positive year-over-year growth rate of 28.2%. The company is scheduled to report its next earnings results on Tuesday, March 6th.
According to Zacks, analysts expect that Editas Medicine will report full year earnings of ($2.92) per share for the current year, with EPS estimates ranging from ($3.51) to ($2.74). For the next fiscal year, analysts forecast that the company will report earnings of ($3.01) per share, with EPS estimates ranging from ($4.33) to ($2.36). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that follow Editas Medicine.
Several equities analysts have weighed in on the company. CLSA assumed coverage on Editas Medicine in a research note on Tuesday, February 13th. They set an “underperform” rating on the stock. Cann reaffirmed a “hold” rating on shares of Editas Medicine in a research note on Friday. SunTrust Banks raised Editas Medicine from a “hold” rating to a “buy” rating and lifted their target price for the company from $17.00 to $45.00 in a research note on Tuesday, January 23rd. Zacks Investment Research cut Editas Medicine from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, Cowen reaffirmed a “buy” rating on shares of Editas Medicine in a research note on Tuesday, November 7th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. Editas Medicine has an average rating of “Hold” and a consensus target price of $30.02.
In other news, CFO Andrew A. F. Hack sold 14,649 shares of Editas Medicine stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $24.68, for a total transaction of $361,537.32. Following the completion of the sale, the chief financial officer now directly owns 5,000 shares in the company, valued at approximately $123,400. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew A. F. Hack sold 5,000 shares of Editas Medicine stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $24.31, for a total value of $121,550.00. Following the sale, the chief financial officer now owns 5,000 shares of the company’s stock, valued at $121,550. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 92,648 shares of company stock valued at $3,052,489. 19.40% of the stock is owned by corporate insiders.
Several institutional investors have recently made changes to their positions in EDIT. First Midwest Bank Trust Division acquired a new stake in Editas Medicine in the 3rd quarter worth approximately $1,349,000. Nisa Investment Advisors LLC lifted its holdings in Editas Medicine by 221.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 71,400 shares of the company’s stock worth $2,194,000 after purchasing an additional 49,200 shares during the last quarter. American Century Companies Inc. acquired a new stake in Editas Medicine in the 3rd quarter worth approximately $7,497,000. Arrowstreet Capital Limited Partnership acquired a new stake in Editas Medicine in the 2nd quarter worth approximately $285,000. Finally, Creative Planning lifted its holdings in Editas Medicine by 155.5% in the 4th quarter. Creative Planning now owns 23,525 shares of the company’s stock worth $723,000 after purchasing an additional 14,318 shares during the last quarter. Institutional investors and hedge funds own 69.66% of the company’s stock.
Editas Medicine (EDIT) traded down $0.97 during trading hours on Monday, reaching $33.82. The company’s stock had a trading volume of 1,192,473 shares, compared to its average volume of 1,800,000. The company has a current ratio of 10.12, a quick ratio of 10.12 and a debt-to-equity ratio of 0.19. Editas Medicine has a 52 week low of $13.12 and a 52 week high of $41.60. The stock has a market cap of $1,530.00 and a PE ratio of -10.44.
TRADEMARK VIOLATION WARNING: “Brokerages Anticipate Editas Medicine Inc (EDIT) to Post -$0.79 Earnings Per Share” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://ledgergazette.com/2018/02/19/brokerages-anticipate-editas-medicine-inc-edit-to-post-0-79-earnings-per-share.html.
About Editas Medicine
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.